.
MergerLinks Header Logo

New Deal


Announced

Completed

GTCR-backed Cole-Parmer completed the acquisition of ZeptoMetrix.

Financials

Edit Data
Transaction Value-
Consideration TypeCash
Capital Owned-
Capital Bid For100%
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

Acquisition

Private Equity

Friendly

Private

Completed

United States

verification panels

Single Bidder

Biotechnology

Majority

Domestic

Synopsis

Edit

GTCR-backed Cole-Parmer, a global manufacturer of proprietary products for fluidics, critical research and process equipment, completed the acquisition of ZeptoMetrix, a life sciences developer and manufacturer of quality control standards and verification panels used in molecular diagnostic testing for infectious diseases. Financial terms were not disclosed. "The addition of ZeptoMetrix is highly complementary to our existing product portfolio within the life sciences market. The acquisition underscores our dedication to serving our customers with unique, differentiated products that help accelerate their research & development programs and support their diagnostic workflows," Bernd Brust, Cole-Parmer Chief Executive Officer.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US